AU2004271183A1 - Cell-based assays for determining drug action - Google Patents

Cell-based assays for determining drug action Download PDF

Info

Publication number
AU2004271183A1
AU2004271183A1 AU2004271183A AU2004271183A AU2004271183A1 AU 2004271183 A1 AU2004271183 A1 AU 2004271183A1 AU 2004271183 A AU2004271183 A AU 2004271183A AU 2004271183 A AU2004271183 A AU 2004271183A AU 2004271183 A1 AU2004271183 A1 AU 2004271183A1
Authority
AU
Australia
Prior art keywords
cells
cell
biomap
parameters
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004271183A
Other languages
English (en)
Inventor
Ellen L. Berg
Eric J. Kunkel
Jennifer Melrose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioseek LLC
Original Assignee
Bioseek LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioseek LLC filed Critical Bioseek LLC
Publication of AU2004271183A1 publication Critical patent/AU2004271183A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
AU2004271183A 2003-09-03 2004-09-02 Cell-based assays for determining drug action Abandoned AU2004271183A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50018003P 2003-09-03 2003-09-03
US60/500,180 2003-09-03
PCT/US2004/028970 WO2005023987A2 (en) 2003-09-03 2004-09-02 Cell-based assays for determining drug action

Publications (1)

Publication Number Publication Date
AU2004271183A1 true AU2004271183A1 (en) 2005-03-17

Family

ID=34272923

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271183A Abandoned AU2004271183A1 (en) 2003-09-03 2004-09-02 Cell-based assays for determining drug action

Country Status (6)

Country Link
US (1) US20070072246A1 (enExample)
EP (1) EP1668361A4 (enExample)
JP (1) JP2007503841A (enExample)
AU (1) AU2004271183A1 (enExample)
CA (1) CA2576406A1 (enExample)
WO (1) WO2005023987A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094992A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for analysis of biological dataset profiles
EP1719051A4 (en) * 2004-02-27 2009-06-17 Bioseek Inc BIOLOGICAL RECORDING OF ASTHMA AND ATOPY
US20060141508A1 (en) * 2004-11-30 2006-06-29 Michelle Palmer Cellular signaling pathway based assays, reagents and kits
US9734282B2 (en) 2005-03-28 2017-08-15 Discoverx Corporation Biological dataset profiling of cardiovascular disease and cardiovascular inflammation
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
US20100009352A1 (en) * 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
EP2023874A4 (en) 2006-06-02 2009-07-08 Bioseek Inc METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
US20100112602A1 (en) * 2006-11-10 2010-05-06 Taylor Lansing D Protein-Protein Interaction Biosensors and Methods of Use Thereof
US20100093613A1 (en) * 2007-03-09 2010-04-15 Kunkel Eric J Methods for identifying agents and their use for the prevention or stabilization of fibrosis
WO2008121896A2 (en) 2007-03-30 2008-10-09 Bioseek, Inc. Methods for classification of toxic agents and counteragents
US8536135B2 (en) * 2008-03-19 2013-09-17 Ontherix, Inc. Adaptive biochemical signatures
CA2718969A1 (en) * 2008-03-19 2009-09-24 Ontherix, Inc. Adaptive biochemical signatures
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
US20170363614A1 (en) * 2014-12-22 2017-12-21 Enumeral Biomedical Holdings, Inc. Methods For Screening Therapeutic Compounds
WO2016168565A1 (en) * 2015-04-16 2016-10-20 President And Fellows Of Harvard College Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring
CN112466403B (zh) * 2020-12-31 2022-06-14 广州基迪奥生物科技有限公司 一种细胞通讯分析方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4007401A (en) * 2000-03-06 2001-09-17 Bioseek Inc Function homology screening
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US7266458B2 (en) * 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
US7623969B2 (en) * 2002-01-31 2009-11-24 The Institute For Systems Biology Gene discovery for the system assignment of gene function
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
EP1620722A4 (en) * 2003-04-23 2008-01-30 Bioseek Inc METHODS FOR CHARACTERIZING SIGNALING PATHWAYS AND COMPOUNDS INTERACTING THEREWITH
WO2004094992A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for analysis of biological dataset profiles

Also Published As

Publication number Publication date
EP1668361A2 (en) 2006-06-14
CA2576406A1 (en) 2005-03-17
WO2005023987A3 (en) 2005-12-08
EP1668361A4 (en) 2008-01-23
JP2007503841A (ja) 2007-03-01
WO2005023987A2 (en) 2005-03-17
US20070072246A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
US8467970B2 (en) Function homology screening
US20070072246A1 (en) Cell-based assays for determining drug action
EP1436617B1 (en) Patient classification
Janes et al. The response of human epithelial cells to TNF involves an inducible autocrine cascade
Junkin et al. High-content quantification of single-cell immune dynamics
Zhang et al. The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B
AU2001240074A2 (en) Function homology screening
AU2001240074A1 (en) Function homology screening
Berg et al. Characterization of compound mechanisms and secondary activities by BioMAP analysis
Dwivedi et al. A Multiscale Model of Interleukin‐6–Mediated Immune Regulation in Crohn's Disease and Its Application in Drug Discovery and Development
Theorell et al. Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation
Mertins et al. An integrative framework reveals signaling-to-transcription events in toll-like receptor signaling
Correa et al. Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors
Damm-Ganamet et al. A prospective virtual screening study: Enriching hit rates and designing focus libraries to find inhibitors of PI3Kδ and PI3Kγ
US20070135997A1 (en) Methods for analysis of biological dataset profiles
Al Shahrani et al. High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk
US8019551B2 (en) Biological dataset profiling of asthma and atopy
von Boehmer T-cell development:: What does Notch do for T cells?
Cakirca et al. Evaluation of Gas6 and sAxl levels during attacks and attack-free periods of familial Mediterranean fever
AU2002341654A1 (en) Patient classification
Baker T Cell Receptor Cross-Reactivity Directed by Antigen Dependent Tuning of Peptide-MHC Molecular Flexibility
Nguyen et al. Tudor I. Oprea1, 2, 3, Cristian G. Bologa1, Søren Brunak4, Allen Campbell5, Gregory N. Gan2, Anna Gaulton6, Shawn M. Gomez7, Rajarshi Guha8, Anne Hersey6, Jayme Holmes1, Ajit Jadhav8, Lars Juhl Jensen4, Gary L. Johnson9, Anneli Karlson6, Andrew R. Leach6, Avi Ma’ayan10, Anna Malovannaya11, Subramani Mani1, Steven L. Mathias1, Michael T. McManus12, Terrence F. Meehan6, Christian von Mering13, Daniel Muthas14, Dac-Trung
Woska Jr et al. Overview of Approaches to the Identification of Inhibitors of Cytokine Action

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application